REGN
NEUTRAL
$772.64
Live
Regeneron Pharmaceuticals, Inc. · NASDAQ
Target $873.24
(+13.0%)
$476.49
52W Range
$821.11
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 01, 2026
Market cap
$81.68B
P/E
18.61
ROE
14.9%
Profit margin
31.4%
Debt/Equity
0.1
Dividend yield
0.5%
AI Analysis
AI-powered fundamental assessment
Confidence
65%
REGN shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics. Price trades at a 165.9% premium to fair value estimate ($290.57), limiting near-term upside from a valuation perspective.
Key Strengths
Strong profitability (31.4% margin)
Low debt with D/E ratio of 0.10
Key Risks
Limited historical data available for full assessment
Price trades at a 165.9% premium to fair value estimate ($290.57), limiting near-term upside from a valuation perspective.
AI Fair Value Estimate
Based on comprehensive analysis
$290.57
-62.4% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
46
Moderate
40
50
60
55
25
AI Verdict
REGN shows bullish fundamentals based on deterministic rules. Financial strength is stable (F-Score 4/9). Key strengths include strong valuation and growth metrics.
Key drivers: Strong profitability (31.4% margin), Low debt with D/E ratio of 0.10, Limited historical data available for full assessment
Confidence
55%
Value
40/100
Rule-based valuation (P/E + Graham).
Positives
- Insufficient data for clear positives.
Watchpoints
- Trades above Graham Number.
- Price trades at a 165.9% premium to fair value estimate ($290.57), limiting near-term upside from a valuation perspective.
Future
50/100
Rule-based growth outlook.
Positives
- Insufficient data for clear positives.
Watchpoints
No urgent risks highlighted.
Past
60/100
Historical performance + price trend: Shares moved +63.8% over 5Y and +22.5% over 1Y.
Positives
- Healthy profit margin of 31.4%.
Watchpoints
No urgent risks highlighted.
Health
55/100
Balance sheet & liquidity (Z-Score: N/A).
Positives
- Low D/E ratio (0.10).
Watchpoints
No urgent risks highlighted.
Dividend
25/100
Dividend policy fallback.
Positives
- Yield: 0.5%.
Watchpoints
- Weak dividend profile (Score: 25/100).
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$772.64
Analyst Target
$873.24
Upside/Downside
+13.0%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for REGN and closest competitors.
Updated 2026-03-31
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
Primary
|
+63.8% | -5.3% | +22.5% | +37.8% | -2.3% | +4.2% |
|
BSX
Boston Scientific Corporation
Peer
|
+39.8% | +16.4% | -36.4% | -40.4% | -14.4% | -6.7% |
|
ELV
Elevance Health, Inc.
Peer
|
-7.3% | -23.6% | -17.6% | -5.1% | +13.4% | +4.7% |
|
CI
The Cigna Group
Peer
|
+20.9% | +7.8% | -17.6% | -7.4% | -7.6% | -1.2% |
|
CVS
CVS Health Corporation
Peer
|
+14.8% | +6.9% | +10.6% | -4.2% | -11.3% | +0.3% |
REG
Regeneron Pharmaceuticals, Inc.
Primary
5Y
+63.8%
3Y
-5.3%
1Y
+22.5%
6M
+37.8%
1M
-2.3%
1W
+4.2%
BSX
Boston Scientific Corporation
Peer
5Y
+39.8%
3Y
+16.4%
1Y
-36.4%
6M
-40.4%
1M
-14.4%
1W
-6.7%
ELV
Elevance Health, Inc.
Peer
5Y
-7.3%
3Y
-23.6%
1Y
-17.6%
6M
-5.1%
1M
+13.4%
1W
+4.7%
CI
The Cigna Group
Peer
5Y
+20.9%
3Y
+7.8%
1Y
-17.6%
6M
-7.4%
1M
-7.6%
1W
-1.2%
CVS
CVS Health Corporation
Peer
5Y
+14.8%
3Y
+6.9%
1Y
+10.6%
6M
-4.2%
1M
-11.3%
1W
+0.3%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.61
Forward P/E
14.72
PEG Ratio
N/A
P/B Ratio
2.54
P/S Ratio
5.7
EV/Revenue
5.13
EV/EBITDA
17.35
Market Cap
$81.68B
Profitability
Profit margins and return metrics
Profit Margin
31.41%
Operating Margin
23.13%
Gross Margin
44.57%
ROE
14.87%
ROA
5.91%
Growth
Revenue and earnings growth rates
Revenue Growth
+2.5%
Earnings Growth
-2.6%
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
-8.0%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.1
Low debt
Current Ratio
4.13
Strong
Quick Ratio
3.28
Excellent
Cash/Share
$83.86
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$3.9B
Gross Margin
84.9%
Op. Margin
23.1%
Net Margin
21.7%
Total Assets
$40.6B
Liabilities
$9.3B
Equity
$31.3B
Debt/Equity
0.30x
Operating CF
$1.2B
CapEx
$-0.3B
Free Cash Flow
$0.9B
FCF Yield
75%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-29
$N/A
2026-01-30
$7.86
-14.0% surprise
2025-10-28
$11.83
+22.7% surprise
2025-08-01
$12.89
+52.7% surprise
Healthcare Sector Comparison
Comparing REGN against 560 companies in the Healthcare sector
(34 bullish, 167 neutral, 359 bearish)
P/E Ratio
18.61
This Stock
vs
75.44
Sector Avg
-75.3%
(Discount)
Return on Equity (ROE)
14.87%
This Stock
vs
-88.14%
Sector Avg
-116.9%
(Below Avg)
Profit Margin
31.41%
This Stock
vs
-16.28%
Sector Avg
-292.9%
(Weaker)
Debt to Equity
0.1
This Stock
vs
2.66
Sector Avg
-96.4%
(Less Debt)
Revenue Growth
2.5%
This Stock
vs
124.04%
Sector Avg
-98.0%
(Slower)
Current Ratio
4.13
This Stock
vs
4.47
Sector Avg
-7.8%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
REGN
Regeneron Pharmaceuticals, Inc.
|
NEUTRAL | $81.68B | 18.61 | 14.9% | 31.4% | $772.64 | |
|
BSX
Boston Scientific Corporation
|
BULLISH | $88.46B | 31.49 | 12.4% | 14.4% | $59.52 | Compare |
|
ELV
Elevance Health, Inc.
|
NEUTRAL | $72.42B | 13.02 | 13.2% | 2.8% | $328.11 | Compare |
|
CI
The Cigna Group
|
NEUTRAL | $71.35B | 12.05 | 15.1% | 2.2% | $267.11 | Compare |
|
CVS
CVS Health Corporation
|
BEARISH | $92.15B | 52.11 | 2.3% | 0.4% | $72.44 | Compare |
REGN
Regeneron...
NEUTRAL
Mkt Cap
$81.7B
P/E
18.6
ROE
14.9%
Price
$772.64
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-02 | RYAN ARTHUR F | Director | Sale | 100 | $78,550 |
| 2026-02-19 | ZOGHBI HUDA Y | Director | Sale | 1,638 | $1,279,812 |
| 2026-02-19 | ZOGHBI HUDA Y | Director | Option Exercise | 1,638 | $617,018 |
| 2026-02-09 | PITOFSKY JASON | Officer | Sale | 2,036 | $1,585,058 |
| 2026-02-09 | RYAN ARTHUR F | Director | Sale | 100 | $77,853 |
| 2026-02-09 | PITOFSKY JASON | Officer | Option Exercise | 1,000 | $492,000 |
| 2026-01-07 | BASSLER BONNIE L | Director | Sale | 1,500 | $1,200,000 |
| 2026-01-07 | BASSLER BONNIE L | Director | Option Exercise | 1,500 | $561,180 |
| 2026-01-02 | ZOGHBI HUDA Y | Director | Stock Award | 155 | - |
| 2026-01-02 | GUARINI KATHRYN PH.D. | Director | Stock Award | 155 | - |
| 2026-01-02 | COLES NEAVELLE ANTHONY | Director | Stock Award | 155 | - |
| 2026-01-02 | THOMPSON CRAIG B | Director | Stock Award | 155 | - |
| 2026-01-02 | SCHENKEIN DAVID P | Director | Stock Award | 155 | - |
| 2026-01-02 | BASSLER BONNIE L | Director | Stock Award | 155 | - |
| 2026-01-02 | POON CHRISTINE A | Director | Stock Award | 155 | - |
RYAN ARTHUR F
Director
2026-03-02
100 shares
·
$78,550
ZOGHBI HUDA Y
Director
2026-02-19
1,638 shares
·
$1,279,812
ZOGHBI HUDA Y
Director
2026-02-19
1,638 shares
·
$617,018
PITOFSKY JASON
Officer
2026-02-09
2,036 shares
·
$1,585,058
RYAN ARTHUR F
Director
2026-02-09
100 shares
·
$77,853
PITOFSKY JASON
Officer
2026-02-09
1,000 shares
·
$492,000
BASSLER BONNIE L
Director
2026-01-07
1,500 shares
·
$1,200,000
BASSLER BONNIE L
Director
2026-01-07
1,500 shares
·
$561,180
ZOGHBI HUDA Y
Director
2026-01-02
155 shares
GUARINI KATHRYN PH.D.
Director
2026-01-02
155 shares
COLES NEAVELLE ANTHONY
Director
2026-01-02
155 shares
THOMPSON CRAIG B
Director
2026-01-02
155 shares
SCHENKEIN DAVID P
Director
2026-01-02
155 shares
BASSLER BONNIE L
Director
2026-01-02
155 shares
POON CHRISTINE A
Director
2026-01-02
155 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
27 analysts
Truist Securities
2026-03-31
Buy
Buy
Barclays
2026-03-06
Overweight
RBC Capital
2026-03-02
Sector Perform
Sector Perform
Guggenheim
2026-02-09
Buy
Buy
JP Morgan
2026-02-02
Overweight
Overweight
Oppenheimer
2026-02-02
Outperform
Outperform
Morgan Stanley
2026-02-02
Equal-Weight
Equal-Weight
Wells Fargo
2026-02-02
Equal-Weight
Equal-Weight
Cantor Fitzgerald
2026-02-02
Overweight
Overweight
Truist Securities
2026-02-02
Buy
Buy
Past News Coverage
Recent headlines mentioning REGN from our newsroom.
Newest → oldest
No matching news yet.